The authors were not able to apply the NT-proBNP inclusion criteria as in the trial (i.e., ≥ 600 pg/ml or, in patients hospitalized for heart failure in the preceding 12 months, ≥ 400 pg/ml), because timing of hospitalization was not known. The gene discussed is NPPB; the disease is heart failure.